Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Athersys, Inc.

Healthcare US ATHXQ

0.0001USD
0.00(0%)

Last update at 2026-06-18T13:30:00Z

Day Range

0.00010.0001
LowHigh

52 Week Range

-0.0001
LowHigh

Fundamentals

  • Previous Close 0.0001
  • Market Cap0.00617M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-28.21700M
  • Revenue TTM0.08M
  • Revenue Per Share TTM0.004
  • Gross Profit TTM -18.69500M
  • Diluted EPS TTM-16.5

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Income before tax -72.53400M -86.95500M -78.76500M -44.58200M
Minority interest - - - -
Net income -72.53400M -86.95500M -78.76500M -44.58200M
Selling general administrative 15.88M 20.07M 15.89M 11.38M
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation 1.42M 1.43M 0.89M 0.70M
Ebit - - - -
Ebitda - - - -
Depreciation and amortization - - - -
Non operating income net other - - - -
Operating income -77.00900M -87.05800M -78.33200M -45.48800M
Other operating expenses - - - -
Interest expense - - - -
Tax provision - - - -
Interest income - - - -
Net interest income - - - -
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense - - - -
Total revenue 5.33M 5.51M 1.43M 5.52M
Total operating expenses 82.33M 92.57M 79.76M 51.01M
Cost of revenue - - - -
Total other income expense net 4.47M 0.10M -0.43300M 0.91M
Discontinued operations - - - -
Net income from continuing ops -72.53400M -86.95500M -78.76500M -44.58200M
Net income applicable to common shares - - - -
Preferred stock and other adjustments - - - -
Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 27.73M 60.18M 59.71M 41.67M
Intangible assets - - - -
Earning assets - - - -
Other current assets 1.03M 1.34M 2.93M 1.19M
Total liab 51.58M 43.81M 28.35M 18.39M
Total stockholder equity -23.85100M 16.37M 31.36M 23.27M
Deferred long term liab - - - -
Other current liab 0.53M - - -
Common stock - - - -
Capital stock 0.02M 0.01000M 0.20M 0.16M
Retained earnings -655.87800M -583.34400M -496.38900M -417.62400M
Other liab - - - -
Good will - - - -
Other assets - - - -
Cash 9.04M 37.41M 51.55M 35.04M
Cash and equivalents - - - -
Total current liabilities 38.44M 29.86M 22.95M 12.84M
Current deferred revenue - - - -
Net debt - - - -
Short term debt - - - -
Short long term debt - - - -
Short long term debt total - - - -
Other stockholder equity - - - -
Property plant equipment - - - -
Total current assets 13.54M 46.03M 54.56M 37.17M
Long term investments - - - -
Net tangible assets - - - -
Short term investments - - - -
Net receivables 0.72M 1.41M 0.09M 0.94M
Long term debt - - - -
Inventory - - - -
Accounts payable 27.77M 16.90M 13.04M 10.12M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income - - - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 2.14M 1.50M 1.35M 1.61M
Deferred long term asset charges - - - -
Non current assets total 14.20M 14.16M 5.15M 4.50M
Capital lease obligations 8.69M 9.77M 0.68M -
Long term debt total - - - -
Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Investments -0.26200M -1.36000M -1.16200M -0.57900M
Change to liabilities - - - -
Total cashflows from investing activities - - - -
Net borrowings - - - -
Total cash from financing activities 30.84M 63.41M 79.48M 19.89M
Change to operating activities - - - -
Net income -72.53400M -86.95500M -78.76500M -44.58200M
Change in cash -28.36900M -14.13900M 16.50M -16.01800M
Begin period cash flow 37.41M 51.55M 35.04M 51.06M
End period cash flow 9.04M 37.41M 51.55M 35.04M
Total cash from operating activities -58.95000M -76.18500M -61.81000M -35.32600M
Issuance of capital stock 31.02M 64.26M 72.78M 20.31M
Depreciation 1.42M 1.43M 0.89M 0.70M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables 3.70M -4.32500M 0.86M 3.78M
Sale purchase of stock - - - -
Other cashflows from financing activities - - - -
Change to netincome - - - -
Capital expenditures 0.40M 1.36M 1.16M 0.58M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 2.95M 0.55M 8.69M 3.71M
Stock based compensation 6.20M 8.56M 7.38M 4.85M
Other non cash items - 0.23M - -
Free cash flow -59.34700M -77.54500M -62.97200M -35.90500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ATHXQ
Athersys, Inc.		 - -% 0.0001 - - 0.08 - 219.47 -0.2581
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Athersys, Inc., a clinical-stage biotechnology company, develops therapies in the regenerative medicine area. Its stem cell product candidate is the MultiStem cell therapy, an allogeneic stem cell product for the treatment of indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other critical care conditions. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On September 24, 2024, the voluntary petition of Athersys, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy along with its affiliates on January 5, 2024.

Athersys, Inc.

3201 Carnegie Avenue, Cleveland, OH, United States, 44115-2634

Key Executives

Name Title Year Born
Ms. Z. Kasey Rosado Interim CFO & Director 1974
Senthil Ranganathan Ph.D. Vice President of Technical Operations NA
Mr. David Russ M.B.A. Vice President of Supply Chain, Finance & Administration NA
Dr. Manal Morsy M.B.A., M.D., PH.D. Executive VP & Head of Global Regulatory Affairs NA
Dr. Robert Mays Ph.D. Executive VP, Head of Regenerative Medicine & Neuroscience Programs NA
Mr. Rakesh Ramachandran MS Head of Information Technology & Communications and VP NA
Dr. Sarah Busch Ph.D. VP of Regenerative Medicine & Head of Business Development NA
Ms. Ellen Gurley Manager of Corporate Communications and Investor Relations NA
Dr. Senthil Ranganathan Ph.D. Vice President of Technical Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.